GlassScriptPhysician profile
William P Maier
NPI 1790735561
$4,498.33
in general payments reported to CMS, 2019-2025
27 companies · $734 in 2025
The $734 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $444 · 2021: $162 · 2022: $360 · 2023: $875 · 2024: $785 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.49 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,003.13 | 2019-2025 | |
| Amgen INC. | $779.67 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Janssen Biotech, INC. | $469.94 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $260.11 | 2020-2025 | |
| Glaxosmithkline, LLC. | $241.42 | 2019-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $215.20 | 2019-2025 | Actemra, Gazyva |
| Novartis Pharmaceuticals Corporation | $211.17 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $199.80 | 2019-2023 | Orencia |
| Horizon Therapeutics Plc | $161.46 | 2020-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $142.93 | 2019 | |
| Celgene Corporation | $142.19 | 2019 | |
| Organon LLC | $114.93 | 2024-2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.35 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $75.65 | 2020-2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $56.89 | 2021-2025 | Saphnelo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $47.89 | 2023-2025 | Hyrimoz, Jubbonti |
| Fresenius Kabi USA, LLC | $45.39 | 2023-2024 | Idacio |
| Ucb, INC. | $33.65 | 2025 | Bimzelx |
| Mylan Institutional INC. | $32.97 | 2023 | Hulio |
| Genzyme Corporation | $31.42 | 2020 | |
| Sobi, INC | $29.88 | 2025 | |
| Lilly USA, LLC | $28.29 | 2019 | |
| Kyowa Kirin, INC. | $23.23 | 2024 | Crysvita |
| Radius Health, INC. | $18.04 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.45 | 2020 | |
| Tersera Therapeutics LLC | $11.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.